KaisermanK, JungH, BenabbadI, KargesB, PolakM, RosilioM. 20 Years of insulin lispro in pediatric type 1 diabetes: a review of available evidence. Pediatr Diabetes, 2016; Jul8. DOI 10.1111/pedi.12401 [Epub ahead of print].
2.
HermansenK, BohlM, SchioldanAG. Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience. Drugs, 2016; 76: 41–74.
3.
BronsveldHK, ter BraakB, KarlstadØ, VestergaardP, Starup-LindeJ, BazelierMT, De BruinML, de BoerA, SiezenCL, van de WaterB, van der LaanJW, SchmidtMK. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res, 2015; 17: 100.
4.
HeiseT, NosekL, Kleino, CoesterH, SvendsenAL, HaahrH. Insulin degludec/aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus. Diabetes Obes Metab, 2016; 17: 659–64.
5.
FulcherGR, ChristiansenJS, BantwalG, Polaszewska-MyszynskaM, MersebachH, AndersenTH, NiskanenLK. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care, 2014; 37: 2084–90.
6.
CampbellMD, WalkerM, TrenellMI, JakovljevicDG, StevensonEJ, BrackenRM, BainSC, WestDJ. Large pre- and postexercise rapid-acting insulin reductions preserve glycemia and prevent early- but not late-onset hypoglycemia in patients with type 1 diabetes. Diabetes Care, 2013; 36: 2217–24.
7.
TyleeT, HirschIB: Costs associated with using different insulin preparations. JAMA, 2015; 314: 665–666.
8.
CarterAW, HeinemannL: If PBMs guard access to drugs, then quis custodiet ipsos custodies? (Who will guard the guardians?). J Diabetes Sci Technol, 2016; Jul4: 1932296816658056. [Epub ahead of print]
9.
Escobedo-MoratillaA, Kuri-Brena Romero deTerreros, Perez-UrizarJ, Barba de la RosaAP: Analytical and biological characterization of a noninnovator insulin glargine and the originator drug product. J Diabetes Sci Technol, 2016; 10: 616–17.
10.
KuhlmannM. K. and Schmidt, A. Production and manufacturing of biosimilar insulins: implications for patients, physicians, and health care systems. Biosimilars, 2014; 4: 114.
11.
CarterAW, HeinemannL, KlonoffDC: Quality control of insulins and biosimilar insulins: What do we know?. J Diabetes Sci Technol, 2016; 10:811–15.
12.
CarterAW: In the biosimilar marketplace will there be 50 ways to leave your insulin?. J Diabetes Sci Technol, 2016; Jan26: pii: 1932296816629488. [Epub ahead of print]
13.
DowlatHA, KuhlmannMK, KhatamiH, Ampudia-BlascoFJ: Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications. Diabetes Obes Metab, 2016; 18: 737–46. DOI 10.1111/dom.12676 [Epub 2016 May 20]
RosenstockJ, HollanderP, BhargavaA, IlagLL, PollomRK, ZielonkaJS, HusterWJ, PrinceMJ. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus(R)) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab, 2015; 17: 734–41.
16.
BlevinsTC, DahlD, RosenstockJ, IlagLL, HusterWJ, ZielonkaJS, PollomRK, PrinceMJ: Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab, 2015; 17: 726–33.
17.
IlagLL, DeegMA, CostiganT, HollanderP, BlevinsTC, EdelmanSV, KonradRJ, OrtmannRA, PollomRK, HusterWJ, ZielonkaJS, PrinceMJ. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus®Insulin glargine in patients with type 1 diabetes mellitus or type 2 diabetes mellitus. Diabetes Obes Metab, 2016; 18: 159–68.
18.
HadjiyianniI, DahlD, LacayaLB, PollomRK, ChangCL, IlagLL: Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Diabetes Obes Metab, 2016; 18: 425–29.
19.
LinnebjergH, LamEC, SegerME, CoutantD, ChuaL, ChongCL, FerreiraMM, SoonD, ZhangX: Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and European Union- and U.S.-approved versions of Lantus insulin glargine in healthy subjects: Three randomized euglycemic clamp studies. Diabetes Care, 2015; 38: 2226–30.
20.
PorcellatiF, LucidiP, BolliGB, FanelliCG: How to accurately establish pharmacokinetics/pharmacodynamics of long-acting insulins in humans: Relevance to biosimilar insulins. Diabetes Care, 2015; 38: 2237–40.
21.
HomeP: Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?. Diabetes Care, 38: 2234–2236, 2015.
22.
HeinemannL: Biosimilar Insulin and Costs: What Can We Expect?. J Diabetes Sci Technol, 2016; 10: 457–462.
23.
BeranD, EwenM, LaingR: Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol, 4: 275–285, 2016.
24.
HeiseT, HövelmannU, BrøndstedL, AdrianCL, NosekL, HaahrH. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab, 2015; 17: 682–88.
25.
Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products. http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm (Accessed 27July2016).
26.
Russell-JonesD, BodeB, de BlockCet al. Double-blind mealtime faster-acting insulin aspart vs. insulin aspart in basal–bolus improves glycemic control in T1D: the Onset® 1 trial. Diabetes, 2016; 65 (Suppl. 1):A77.
27.
BoweringK, CaseC, HarveyJ, et al.Abstract 240-OR/240. Faster-Acting Insulin Aspart vs. Insulin Aspart as Part of Basal-Bolus Therapy Improves Postprandial Glycemic Control in Uncontrolled T2D in the Double-Blinded Onset 2 Trial. Presented at: ADA 76th Scientific Sessions; June 10–14, 2016; New Orleans, LA.
28.
Heiseet al.Ultra-Rapid BioChaperone® Lispro Ameliorates Postprandial Blood Glucose (PPG) Control Compared with Humalog® in Subjects with Type 1 Diabetes Mellitus (NCT02528396) 294-OR. Presented at: ADA 76th Scientific Sessions; June 10–14, 2016; New Orleans, LA.
29.
CengizE, BodeB, Van NameM, TamborlaneWV. Moving toward the ideal insulin for insulin pumps. Expert Rev Med Devices, 2016; 13: 57–69.
